Movement Alert｜Insilico Medicine Rises 5.95% in Regular Trading, SK Biopharmaceuticals USD 2.5 Billion AI-Driven Collaboration Continues to Boost Sentiment

Market Focus

Jun 23

On June 23, Insilico Medicine rose 5.95% in regular trading, trading at HKD 42.4/share, with turnover of HKD 85.69 million, extending the prior session's strong momentum.

On the news front, the company announced on June 22 a research collaboration with SK Biopharmaceuticals targeting AI-driven innovative drug candidates for CNS neuroimmunology disorders. Under the agreement, Insilico Medicine is eligible for up to USD 18 million in upfront and near-term milestone payments, with the potential total deal value exceeding USD 2.5 billion, encompassing development, regulatory, and commercialization milestones as well as single-digit royalties on net sales. This marks the latest in a series of partnerships secured this year — including deals with Servier, Hengtai Bio, Qilu Pharma, Eli Lilly, and others — bringing total new signed deal value to nearly USD 6.5 billion. The collaboration further validates the company's Pharma.AI platform capabilities, with multiple brokerages initiating coverage with Buy ratings and UBS setting a target price of HKD 77.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1140175005"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140175005\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140175005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140175005","market":"us","top_or_hot":-1,"title":"Movement Alert｜Insilico Medicine Rises 5.95% in Regular Trading, SK Biopharmaceuticals USD 2.5 Billion AI-Driven Collaboration Continues to Boost Sentiment","media":"Market Focus","content":"<p><p>On June 23, Insilico Medicine rose 5.95% in regular trading, trading at HKD 42.4/share, with turnover of HKD 85.69 million, extending the prior session's strong momentum.</p><p>On the news front, the company announced on June 22 a research collaboration with SK Biopharmaceuticals targeting AI-driven innovative drug candidates for CNS neuroimmunology disorders. Under the agreement, Insilico Medicine is eligible for up to USD 18 million in upfront and near-term milestone payments, with the potential total deal value exceeding USD 2.5 billion, encompassing development, regulatory, and commercialization milestones as well as single-digit royalties on net sales. This marks the latest in a series of partnerships secured this year — including deals with Servier, Hengtai Bio, Qilu Pharma, Eli Lilly, and others — bringing total new signed deal value to nearly USD 6.5 billion. The collaboration further validates the company's Pharma.AI platform capabilities, with multiple brokerages initiating coverage with Buy ratings and UBS setting a target price of HKD 77.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Insilico Medicine Rises 5.95% in Regular Trading, SK Biopharmaceuticals USD 2.5 Billion AI-Driven Collaboration Continues to Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Insilico Medicine Rises 5.95% in Regular Trading, SK Biopharmaceuticals USD 2.5 Billion AI-Driven Collaboration Continues to Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, Insilico Medicine rose 5.95% in regular trading, trading at HKD 42.4/share, with turnover of HKD 85.69 million, extending the prior session's strong momentum.</p><p>On the news front, the company announced on June 22 a research collaboration with SK Biopharmaceuticals targeting AI-driven innovative drug candidates for CNS neuroimmunology disorders. Under the agreement, Insilico Medicine is eligible for up to USD 18 million in upfront and near-term milestone payments, with the potential total deal value exceeding USD 2.5 billion, encompassing development, regulatory, and commercialization milestones as well as single-digit royalties on net sales. This marks the latest in a series of partnerships secured this year — including deals with Servier, Hengtai Bio, Qilu Pharma, Eli Lilly, and others — bringing total new signed deal value to nearly USD 6.5 billion. The collaboration further validates the company's Pharma.AI platform capabilities, with multiple brokerages initiating coverage with Buy ratings and UBS setting a target price of HKD 77.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1140175005","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140175005","pubTimestamp":1782179434,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, Insilico Medicine rose 5.95% in regular trading, trading at HKD 42.4/share, with turnover of HKD 85.69 million, extending the prior session's strong momentum.On the news front, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"动静提示|英矽智能常规交易涨5.95%SK生物制药25亿美元AI驱动合作持续提振人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On June 23, Insilico Medicine rose 5.95% in regular trading, trading at HKD 42.4/share, with turnover of HKD 85.69 million, extending the prior session's strong momentum.On the news front, the company announced on June 22 a research collaboration with SK Biopharmaceuticals targeting AI-driven innovative drug candidates for CNS neuroimmunology disorders. Under the agreement, Insilico Medicine is eligible for up to USD 18 million in upfront and near-term milestone payments, with the potential total deal value exceeding USD 2.5 billion, encompassing development, regulatory, and commercialization milestones as well as single-digit royalties on net sales. This marks the latest in a series of partnerships secured this year — including deals with Servier, Hengtai Bio, Qilu Pharma, Eli Lilly, and others — bringing total new signed deal value to nearly USD 6.5 billion. The collaboration further validates the company's Pharma.AI platform capabilities, with multiple brokerages initiating coverage with Buy ratings and UBS setting a target price of HKD 77.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}